onasemnogene abeparvovec
AXP000250.1 · Viral vector gene therapy
- Platform
- AAV9 vector
- Targets
- SMN1
- Originator
- Nationwide Children's Hospital / AveXis
- Sponsor
- Novartis Gene Therapies
Names
| Name | Type | Source |
|---|---|---|
| onasemnogene abeparvovec | preferred name | curator |
| Itvisma | brand | fda |
| Zolgensma | brand | fda |
| OAV-101 | code | curator |
| AVXS-101 | former code | curator |
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus 9
- Strain
- AAV9
- Replication
- non replicating
- Modifications
- self-complementary genome, cytomegalovirus enhancer/chicken beta-actin hybrid promoter
- Transgenes
- SMN1
- Route
- intravenous, intrathecal
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2019-05-24 | approved | Zolgensma | Paediatric patients under 2 years with spinal muscular atrophy and bi-allelic SMN1 mutations (intravenous) | source |
| PMDA | JP | 2020-03-19 | approved | Zolgensma | Spinal muscular atrophy, including genetically diagnosed pre-symptomatic SMA, in patients who have tested negative for anti-AAV9 antibodies | source |
| EMA | EU | 2020-05-18 | approved | Zolgensma | 5q SMA with a bi-allelic SMN1 mutation and either a clinical diagnosis of type 1 or up to 3 SMN2 copies; conditional at first, full from 2022-05-17 | source |
| FDA | US | 2025-11-24 | approved | Itvisma | Spinal muscular atrophy in patients 2 years and older with a confirmed SMN1 mutation (intrathecal) | source |
| PMDA | JP | 2026-04-03 | approved | Zolgensma | Spinal muscular atrophy; the intrathecal formulation, approved as a separate product (Zolgensma Suspension for Intrathecal Injection). PMDA has not yet published a review report for this approval, so only the product and the date are recorded here | source |
Clinical trials (22)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07737756 | A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia | Not yet recruiting | 2026-11-30 | 2027-02-28 | 6 | Spinal Muscular Atrophy | |
| NCT07444450 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec | Recruiting | Phase 3 | 2026-10-31 | 2029-07-27 | 42 | Muscular Atrophy, Spinal |
| NCT07767890 | A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients | Recruiting | 2026-10-07 | 2031-03-31 | 80 | Spinal Muscular Atrophy | |
| NCT07448610 | ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM) | Recruiting | Phase 4 | 2026-08-27 | 2032-05-03 | 36 | Spinal Muscular Atrophy |
| NCT06019637 | A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma | Recruiting | 2023-11-27 | 2042-01-02 | 50 | Spinal Muscular Atrophies | |
| NCT05386680 | Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam | Completed | Phase 3 | 2023-01-12 | 2024-11-29 | 27 | Spinal Muscular Atrophy |
| NCT05335876 | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials | Active not recruiting | Phase 3 | 2022-12-19 | 2031-04-29 | 20 | Spinal Muscular Atrophy (SMA) |
| NCT05575011 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec | Active not recruiting | Phase 1 | 2022-10-10 | 2031-11-14 | 62 | Healthy Volunteer; Muscular Atrophy, Spinal |
| NCT05089656 | Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) | Completed | Phase 3 | 2022-02-01 | 2024-11-12 | 126 | Type 2 Spinal Muscular Atrophy |
| NCT05073133 | Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) | Completed | Phase 4 | 2021-11-04 | 2023-08-08 | 16 | Muscular Atrophy, Spinal |
| NCT04851873 | Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) | Completed | Phase 3 | 2021-09-08 | 2023-06-13 | 24 | Spinal Muscular Atrophy |
| NCT04488133 | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) | Completed | Phase 4 | 2021-01-04 | 2025-10-09 | 46 | Muscular Atrophy, Spinal |
| NCT04042025 | Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi | Active not recruiting | Phase 3 | 2020-02-10 | 2035-12-31 | 85 | SMA; Spinal Muscular Atrophy Type I; Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III |
| NCT03837184 | Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies | Completed | Phase 3 | 2019-05-31 | 2021-06-29 | 2 | Spinal Muscular Atrophy Type I |
| NCT04174157 | Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) | Recruiting | 2018-09-25 | 2038-06-30 | 700 | Spinal Muscular Atrophy (SMA) | |
| NCT03461289 | Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 | Completed | Phase 3 | 2018-08-16 | 2020-09-11 | 33 | SMA |
| NCT03505099 | Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 | Completed | Phase 3 | 2018-04-02 | 2021-06-15 | 30 | Spinal Muscular Atrophy |
| NCT03381729 | Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy | Terminated | Phase 1 | 2017-12-14 | 2021-11-18 | 32 | Spinal Muscular Atrophy |
| NCT03306277 | Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 | Completed | Phase 3 | 2017-10-24 | 2019-11-12 | 22 | Gene Therapy; SMA - Spinal Muscular Atrophy |
| NCT03421977 | Long-Term Follow-up Study for Patients From AVXS-101-CL-101 | Active not recruiting | 2017-09-21 | 2030-12-02 | 13 | Spinal Muscular Atrophy 1 | |
| NCT02122952 | Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 | Completed | Phase 1 | 2014-05-05 | 2017-12-15 | 15 | Spinal Muscular Atrophy 1 |
| NCT03955679 | AveXis Managed Access Program Cohort for Access to AVXS-101 | Approved for marketing | Spinal Muscular Atrophy |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41217888 | Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry. | Journal of neuromuscular diseases | 2026 | cited by trial NCT04174157 |
| PMID 41360993 | Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial. | Nature medicine | 2026 | cited by trial NCT05089656 |
| PMID 41360995 | Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. | Nature medicine | 2026 | cited by trial NCT05386680 |
| PMID 41431300 | Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry. | Brain : a journal of neurology | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41545588 | Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy. | Nature medicine | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41718941 | Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series. | Advances in therapy | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41757676 | Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye. | Muscle & nerve | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41795276 | Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report. | Brain & development | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41854353 | Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry. | Annals of clinical and translational neurology | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41964328 | Risdiplam Add-On Therapy Following Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy and 2 SMN2 Copies: A Multi-Center Case Series. | Muscle & nerve | 2026 | name in title: onasemnogene abeparvovec |
| PMID 42016922 | Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study. | EClinicalMedicine | 2026 | cited by trial NCT02122952 |
| PMID 42265796 | Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan. | Annals of clinical and translational neurology | 2026 | cited by trial NCT04174157 |
| PMID 42400303 | Adeno-Associated Virus Gene Therapy for Spinal Muscular Atrophy Induces Hepatotoxicity via Cytokine and Macrophage Activation. | Liver international : official journal of the International Association for the Study of the Liver | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42563034 | Longitudinal Dosing Patterns and Treatment Costs Among Patients with Spinal Muscular Atrophy Initiating Nusinersen and Risdiplam. | Advances in therapy | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42601027 | Gene therapy benefits in a small cohort of symptomatic 5q spinal muscular atrophy patients and real world pediatric outcomes. | Jornal de pediatria | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42612481 | Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility. | Neuromuscular disorders : NMD | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 39689850 | Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report. | Neuropediatrics | 2025 | name in title: onasemnogene abeparvovec |
| PMID 39804575 | Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study. | Neurology | 2025 | cited by trial NCT04851873 |
| PMID 39955617 | Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40013321 | Characteristics of Patients With Spinal Muscular Atrophy Who Have Switched Treatments: A Multi-Center Experience in the United Kingdom. | Muscle & nerve | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40025752 | Early Treatment in Preterm Twins With Spinal Muscular Atrophy. | Journal of child neurology | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40269260 | Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy. | Gene therapy | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40365794 | Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec. | Pediatrics international : official journal of the Japan Pediatric Society | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40533496 | Thrombotic microangiopathy following gene therapy for 5q-spinal muscular atrophy. | Gene therapy | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40538493 | Eculizumab for Thrombotic Microangiopathy Induced by Onasemnogene Abeparvovec in Spinal Muscular Atrophy. | Case reports in nephrology and dialysis | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40624473 | Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series. | BMC neurology | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40625130 | REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France. | Journal of neuromuscular diseases | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40630496 | Real-world outcomes of spinal muscular atrophy treatment with onasemnogene abeparvovec in Croatia: a comprehensive case series and literature review. | Frontiers in medicine | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40705999 | Reduction of Preexisting AAV9 Antibody Titers Before Onasemnogene Abeparvovec Administration in Twins With Spinal Muscular Atrophy. | Neurology | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40863714 | Eosinophilic Esophagitis in a 3-Year-Old Girl with Spinal Muscular Atrophy Type 1: The First Reported Case. | Pediatric reports | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40956616 | Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. | The Journal of clinical investigation | 2025 | cited by trial NCT04488133 |
| PMID 40965051 | Treatment Outcome of Risdiplam and Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy Dependent on Prolonged Invasive Ventilation. | Journal of paediatrics and child health | 2025 | name in title: onasemnogene abeparvovec |
| PMID 41122612 | Administration of Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy and PCR-Confirmed SARS-CoV-2 Infection. | Cureus | 2025 | name in title: onasemnogene abeparvovec |
| PMID 37657961 | Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up. | Brain & development | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 38233181 | Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1. | The Kurume medical journal | 2024 | name in title: onasemnogene abeparvovec |
| PMID 38250783 | Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. | Journal of neuromuscular diseases | 2024 | name in title: onasemnogene abeparvovec |
| PMID 38306058 | Repeated AAV9 Titer Determination in a Presymptomatic SMA Patient with Three SMN2 Gene Copies - A Case Report. | Journal of neuromuscular diseases | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 38676690 | [Experience of the treatment of spinal muscular atrophy type 3 Kugelberg-Welander with Nusinersen]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 38733387 | JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. | Journal of neurology | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 38790585 | Onasemnogene Abeparvovec Administration via Peripherally Inserted Central Catheter: A Case Report. | Children (Basel, Switzerland) | 2024 | name in title: onasemnogene abeparvovec |
| PMID 38839888 | Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort. | Gene therapy | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 39111255 | Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1. | Neuromuscular disorders : NMD | 2024 | name in title: onasemnogene abeparvovec |
| PMID 39327607 | Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening. | Orphanet journal of rare diseases | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 39342433 | Onasemnogene-abeparvovec administration to premature infants with spinal muscular atrophy. | Annals of clinical and translational neurology | 2024 | name in title: onasemnogene abeparvovec |
| PMID 39370660 | Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study. | Muscle & nerve | 2024 | name in abstract: onasemnogene abeparvovec |
| PMID 39625559 | Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. | European journal of pediatrics | 2024 | name in title: onasemnogene abeparvovec |
| PMID 35474244 | Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec -routine care evidence. | Gene therapy | 2023 | name in title: onasemnogene abeparvovec |
| PMID 35606491 | Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. | Gene therapy | 2023 | name in title: onasemnogene abeparvovec |
| PMID 36855136 | Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study. | BMC neurology | 2023 | name in title: onasemnogene abeparvovec |
| PMID 37091744 | Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth. | Molecular genetics and metabolism reports | 2023 | name in abstract: onasemnogene abeparvovec |
| PMID 37149951 | Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience. | Pediatric neurology | 2023 | name in abstract: onasemnogene abeparvovec |
| PMID 37598295 | Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec. | Molecular therapy : the journal of the American Society of Gene Therapy | 2023 | name in title: onasemnogene abeparvovec |
| PMID 37780708 | Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment. | Frontiers in neurology | 2023 | name in abstract: onasemnogene abeparvovec |
| PMID 37841286 | A homozygous missense variant in the YG box domain in an individual with severe spinal muscular atrophy: a case report and variant characterization. | Frontiers in cellular neuroscience | 2023 | name in abstract: onasemnogene abeparvovec |
| PMID 37907848 | Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports. | BMC neurology | 2023 | name in title: onasemnogene abeparvovec |
| PMID 38090542 | Sequential treatment with nusinersen, Zolgensma® and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report. | Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology | 2023 | name in title: Zolgensma |
| PMID 34388834 | [Thrombotic Microangiopathy (TMA) after Gene Replacemant Therapy (GRT) due to Spinal Muscular Atrophy: Case Summary and Recommendations for Treatment]. | Klinische Padiatrie | 2022 | name in abstract: onasemnogene abeparvovec |
| PMID 34756190 | Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. | The Lancet. Child & adolescent health | 2022 | name in title: onasemnogene abeparvovec |
| PMID 35351784 | Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA. | Neurology | 2022 | name in title: onasemnogene abeparvovec |
| PMID 35584395 | Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. | Blood advances | 2022 | name in abstract: onasemnogene abeparvovec |
| PMID 35715566 | Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. | Nature medicine | 2022 | cited by trial NCT03505099 |
| PMID 35715567 | Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. | Nature medicine | 2022 | cited by trial NCT03505099 |
| PMID 35924856 | Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy. | Journal of clinical pharmacy and therapeutics | 2022 | name in abstract: onasemnogene abeparvovec |
| PMID 36125439 | Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma. | Human gene therapy | 2022 | name in title: Zolgensma |
| PMID 36349185 | Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam. | Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology | 2022 | name in title: onasemnogene abeparvovec |
| PMID 33259859 | Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. | The Journal of pediatrics | 2021 | name in title: onasemnogene abeparvovec |
| PMID 33743238 | Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. | The Lancet. Neurology | 2021 | cited by trial NCT03306277 |
| PMID 33959970 | Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. | Muscle & nerve | 2021 | name in abstract: onasemnogene abeparvovec |
| PMID 33999158 | Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. | JAMA neurology | 2021 | cited by trial NCT03421977 |
| PMID 34383289 | Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. | Drug safety | 2021 | cited by trial NCT02122952 |
| PMID 34536405 | Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. | The Lancet. Neurology | 2021 | cited by trial NCT03461289 |
| PMID 34608334 | Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. | Nature medicine | 2021 | name in title: onasemnogene abeparvovec |
| PMID 32515646 | Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec. | Journal of child neurology | 2020 | name in title: onasemnogene abeparvovec |
| PMID 33003005 | Spinal Muscular Atrophy. | Continuum (Minneapolis, Minn.) | 2020 | name in abstract: onasemnogene abeparvovec |
| PMID 30548438 | Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. | Pediatric pulmonology | 2019 | cited by trial NCT02122952 |
| PMID 30879249 | Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. | Advances in therapy | 2019 | cited by trial NCT02122952 |
| PMID 31277975 | Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. | Pediatric neurology | 2019 | cited by trial NCT02122952 |
| PMID 31488615 | Combination therapy with nusinersen and AVXS-101 in SMA type 1. | Neurology | 2019 | name in title: AVXS-101 |
| PMID 29091557 | Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. | The New England journal of medicine | 2017 | cited by trial NCT02122952 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39794476 | Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy. | Gene therapy | 2026 | name in abstract: Zolgensma |
| PMID 40148593 | Organoids - the future of pre-clinical development of AAV gene therapy for CNS disorders. | Gene therapy | 2026 | name in abstract: Zolgensma |
| PMID 40169808 | Early life safety profiling of gene therapy for spinal muscular atrophy. | Gene therapy | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 40569556 | Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy. | The European journal of health economics : HEPAC : health economics in prevention and care | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41109767 | Updates of spinal muscular atrophy in advanced therapies. | Journal of the Formosan Medical Association = Taiwan yi zhi | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41212681 | Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerations. | Journal of neuromuscular diseases | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41284552 | Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland-part I-systematic literature review and existing evidence. | Journal of neuromuscular diseases | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41343897 | Promises past and future - Gene therapy and the actualisation of future expectations. | Social science & medicine (1982) | 2026 | name in abstract: Zolgensma |
| PMID 41398093 | Clinical relevance of zebrafish for gene variants testing. Proof-of-principle with SMN1/SMA. | EMBO molecular medicine | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41496894 | CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. | Molecular therapy. Nucleic acids | 2026 | name in abstract: Zolgensma |
| PMID 41508057 | Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes. | Orphanet journal of rare diseases | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41566962 | Fusionless spinal surgery in children with spinal muscular atrophy type 1 with bipolar system: a preliminary communication. | Journal of pediatric orthopedics. Part B | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41574584 | The High Cost of Gene Therapy: Managing Onasemnogene Abeparvovec's Economic Impact. | The Annals of pharmacotherapy | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41606122 | Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. | Nature medicine | 2026 | name in title: onasemnogene abeparvovec |
| PMID 41671781 | Longitudinal assessment of respiratory status utilising the amended Great Ormond Street Respiratory Score in treated spinal muscular atrophy type 1 children. | Neuromuscular disorders : NMD | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41680498 | Patient reported outcome measures in spinal muscular atrophy and duchenne muscular dystrophy: review of instruments and their inclusion in clinical and regulatory processes. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41699720 | Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial. | Orphanet journal of rare diseases | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41720432 | Skeletal muscle in spinal muscular atrophy: Critical insights from pathogenesis to therapeutic strategies. | Neurobiology of disease | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41782369 | Low-dose AAV9-SMN1 with CNS-selective expression delivers efficacy and favorable safety in spinal muscular atrophy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41813830 | Securitization as a means to pay for cell and gene therapies for orphan diseases: a simulation study. | Gene therapy | 2026 | name in abstract: Zolgensma |
| PMID 41817636 | RNA biomarkers in spinal muscular atrophy: enhancing pathogenesis understanding and guiding precision medicine. | Cellular and molecular life sciences : CMLS | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 41933930 | Adeno-Associated Virus Gene Delivery to Hard-to-Transduce Tissues: Biological Barriers, Engineering Strategies, and Clinical Challenges. | Human gene therapy | 2026 | name in abstract: Zolgensma |
| PMID 41944036 | Incidence, Timing and Clinical Significance of Immune-Mediated Myocardial Injury and Myocarditis After Gene Replacement Therapy: A Systematic Review and Meta-Analysis. | Circulation. Heart failure | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42023171 | Hip displacement management in spinal muscular atrophy in the era of disease modifying therapies: a Delphi consensus study in the UK. | EClinicalMedicine | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42084965 | Onasemnogene Abeparvovec in Early-Onset Spinal Muscular Atrophy: An Indian Experience. | Annals of Indian Academy of Neurology | 2026 | name in title: onasemnogene abeparvovec |
| PMID 42095821 | [Spinal muscular atrophy: Clinical and genetic aspects, and therapeutic alternatives]. | Revista medica del Instituto Mexicano del Seguro Social | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42097918 | Management of spinal muscular atrophy: nursing clinical commentary and best practices update. | Journal of pediatric nursing | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42104248 | Exploring the phenotypic and genotypic spectrum of spinal muscular atrophy in Bangladeshi children. | BMC neurology | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42105903 | Beyond SMN1 mutation: environmental predispositions and epigenetic contributors to phenotypic variability and disease severity in spinal muscular atrophy. | Neuroscience | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42137283 | Elective preterm birth for earlier spinal muscular atrophy treatment. | Molecular therapy. Advances | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42157963 | Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G. | Molecular therapy. Advances | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42161221 | Characterization of Safety Signals for Spinal Muscular Atrophy Treatments in Children Aged 0 to 3 Years Potential Safety Patterns for Further Investigation. | Pediatric neurology | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42177183 | Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice. | Nature communications | 2026 | name in abstract: Zolgensma |
| PMID 42203536 | Advancements in Prenatal Diagnosis and Potential Fetal Therapies for Spinal Muscular Atrophy. | Clinical therapeutics | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42211742 | External controls for rare disease drug development: Lessons for emerging and advanced therapeutic modalities. | Molecular therapy. Advances | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42233939 | Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan. | Value in health regional issues | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42240059 | Determinants of hepatic enzyme elevations following onasemnogene abeparvovec: Results from a unified immunomodulation protocol. | Journal of neuromuscular diseases | 2026 | name in title: onasemnogene abeparvovec |
| PMID 42260056 | Modeling the Budget Impact of Disease-Modifying Therapies in Infantile-Onset Spinal Muscular Atrophy. | Clinical drug investigation | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42309883 | Gene therapy in pediatric patients with spinal muscular atrophy in Kazakhstan: Challenges and achievements. | Pediatrics and neonatology | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42432779 | Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials. | Trials | 2026 | name in abstract: Zolgensma |
| PMID 42449943 | Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS). | International journal of molecular sciences | 2026 | name in abstract: Zolgensma |
| PMID 42582471 | Therapeutic strategies for spinal muscular atrophy: the history and future perspective. | Frontiers in human neuroscience | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42658895 | Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects. | Journal of neuromuscular diseases | 2026 | name in title: onasemnogene abeparvovec |
| PMID 42668237 | 289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands. | Neuromuscular disorders : NMD | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42713019 | Spinal muscular atrophy in the disease-modifying therapy era: successes, limitations and future directions. | Frontiers in molecular medicine | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42749594 | Consensus on gene therapy for spinal muscular atrophy in Taiwan. | Journal of the Formosan Medical Association = Taiwan yi zhi | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42776081 | Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease. | Expert reviews in molecular medicine | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42779866 | P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy. | medRxiv : the preprint server for health sciences | 2026 | name in abstract: Zolgensma |
| PMID 42799810 | Real-World Treatment Patterns in Patients with Spinal Muscular Atrophy Receiving Multiple Disease-Modifying Therapies. | Advances in therapy | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42807701 | Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations. | Frontiers in pharmacology | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42869088 | Consensus on the Use of Intrathecal Gene Therapy for Spinal Muscular Atrophy. | Neuropediatrics | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42894980 | Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal. | International journal of technology assessment in health care | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42903708 | The role of vascular pathology in SMA: implications for pathogenesis and treatment. | Frontiers in cellular neuroscience | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 42983461 | Use of European registries to characterise the changing landscape of disease progression and treatment of spinal muscular atrophy (SMA): opportunities, pitfalls and challenges. | Orphanet journal of rare diseases | 2026 | name in abstract: onasemnogene abeparvovec |
| PMID 43016315 | Indirect treatment comparisons of nusinersen versus onasemnogene abeparvovec-brve in treatment-naïve and -experienced spinal muscular atrophy patients. | Journal of medical economics | 2026 | name in title: onasemnogene abeparvovec |
| PMID 39039945 | Genetic counselors' awareness and attitudes regarding gene therapies. | Journal of genetic counseling | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39333302 | Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis. | Applied health economics and health policy | 2025 | name in title: onasemnogene abeparvovec |
| PMID 39368017 | Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. | PharmacoEconomics | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39426797 | Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil. | Jornal de pediatria | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39604484 | Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis. | Gene therapy | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39708835 | Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders. | Seminars in respiratory and critical care medicine | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39739027 | Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies. | European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39913410 | Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database. | PloS one | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39969920 | The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis. | Respiratory care | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 39982664 | Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. | The European journal of health economics : HEPAC : health economics in prevention and care | 2025 | name in title: onasemnogene abeparvovec |
| PMID 39993407 | The Legal Issues Regarding the Reimbursement of Drugs Used to Treat Muscular Atrophy and the Actual Situation in the Slovak Republic. | European journal of health law | 2025 | name in abstract: Zolgensma |
| PMID 40009418 | Safety of Onasemnogene Abeparvovec Administration to Type 1 SMA Patients Who Have Received Risdiplam. | Journal of clinical neuromuscular disease | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40022865 | Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies. | Neuromuscular disorders : NMD | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40104176 | Real-world evidence in spinal muscular atrophy: addressing heterogeneity of populations and treatment comparisons. | The Lancet regional health. Europe | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40253479 | Structural characterization of antibody-responses following Zolgensma treatment for AAV capsid engineering to expand patient cohorts. | Nature communications | 2025 | name in title: Zolgensma |
| PMID 40289052 | Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals. | Neurology and therapy | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40329332 | Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study. | Orphanet journal of rare diseases | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40364205 | Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance. | Journal of clinical medicine | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40382143 | Gene replacement therapy to restore polyamine metabolism in a Snyder-Robinson syndrome mouse model. | Methods in enzymology | 2025 | name in abstract: Zolgensma |
| PMID 40509660 | Costs of Treating Onasemnogene Abeparvovec-Xioi-Induced Liver Injury. | Pharmacology research & perspectives | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40538117 | Switching disease-modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes. | British journal of clinical pharmacology | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40622452 | Early Intervention and Speed-to-Effect in Spinal Muscular Atrophy Type 1 Following Onasemnogene Abeparvovec Gene Replacement Therapy: Results of aPost-Hoc Analysis of Pooled Clinical Study Data. | Neurology and therapy | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40765022 | Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements. | Cost effectiveness and resource allocation : C/E | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40778350 | Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study. | Lancet regional health. Americas | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40803915 | Real-world experience with switch to onasemnogene abeparvovec after initial therapy with nusinersen or risdiplam. | Neuromuscular disorders : NMD | 2025 | name in title: onasemnogene abeparvovec |
| PMID 40805927 | Pharmacoeconomic Profiles of Advanced Therapy Medicinal Products in Rare Diseases: A Systematic Review. | Healthcare (Basel, Switzerland) | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40868194 | Transforming Spinal Muscular Atrophy: From Pivotal Trials to Real-World Evidence and Future Therapeutic Frontiers in Types 1 and 2. | Biomedicines | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40868246 | Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives. | Biomedicines | 2025 | name in abstract: Zolgensma |
| PMID 40879810 | Combination therapies in spinal muscular atrophy: a systematic review. | European journal of pediatrics | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 40986347 | Biomarkers of immune dysregulation and posttreatment inflammation in spinal muscular atrophy. | Proceedings of the National Academy of Sciences of the United States of America | 2025 | name in abstract: Zolgensma |
| PMID 41001995 | SNAC: A Single-Nuclei Atlas of Capsid Distribution in Nonhuman Primate Eye. | Human gene therapy | 2025 | name in abstract: Zolgensma |
| PMID 41007120 | Reduction in Perioperative Risk in Patients with Spinal Muscular Atrophy Following the Release of Disease-Modifying Therapies: An Analysis of the National Surgical Quality Improvement Program Database. | Children (Basel, Switzerland) | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41060652 | Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1. | JAMA network open | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41133701 | Quebec Spinal Muscular Atrophy Newborn Screening Program: The First Year Experience. | International journal of neonatal screening | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41149786 | Diverging Safety Signals: A Trend Analysis of Suspected Adverse Drug Reactions Reporting for Spinal Muscular Atrophy Therapies in the European Union. | Neurology international | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41235102 | Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives. | Current genomics | 2025 | name in abstract: Zolgensma |
| PMID 41283364 | Treating Presymptomatic Spinal Muscular Atrophy Patients with Onasemnogene Abeparvovec in Italy: The Role of the National Health System and Drug Supply. Comment on Zaidman et al. Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States. Int. J. Neonatal Screen. 2024, 10, 58. | International journal of neonatal screening | 2025 | name in title: onasemnogene abeparvovec |
| PMID 41283841 | [Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2025 | name in title: onasemnogene abeparvovec |
| PMID 41299848 | Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence. | The Journal of international medical research | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41303705 | Evaluation of the Telomere Length in Patients with Spinal Muscular Atrophy. | International journal of molecular sciences | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41350752 | Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review. | Orphanet journal of rare diseases | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41362291 | Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments. | Molecular therapy. Methods & clinical development | 2025 | name in abstract: Zolgensma |
| PMID 41524367 | [Pharmacoeconomic evaluation of spinal muscular atrophy therapy in patients with four SMN2 copies diagnosed through newborn screening]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41607656 | Circulating Tau Profiles in Pediatric and Adult Patients with Spinal Muscular Atrophy. | medRxiv : the preprint server for health sciences | 2025 | name in abstract: onasemnogene abeparvovec |
| PMID 41607729 | Five-year disease-modifying therapeutic experience of 102 Chinese paediatric 5q-spinal muscular atrophy: a retrospective analysis. | Brain communications | 2025 | name in abstract: Zolgensma |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01EB034573 | Engineering the biology of AAV secretion and production | DUKE UNIVERSITY | ASOKAN, ARAVIND | 2023–2026 | name in abstract: Zolgensma |
| R01NS076991 | Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies | UNIV OF MASSACHUSETTS MED SCH WORCESTER | GAO, GUANGPING | 2025–2026 | name in abstract: Zolgensma |
| R41NS143578 | Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC | NEUROGT, INC. | FU, HAIYAN | 2025–2026 | name in abstract: Zolgensma |
| R21AI180416 | Studies of the KIAA0319L-mediated productive transduction pathways of rAAV vectors | UNIVERSITY OF KANSAS MEDICAL CENTER | QIU, JIANMING | 2024–2025 | name in abstract: Zolgensma |
| R21AI171265 | Mechanism of the Membrane-Associated Accessory Protein (MAAP) in rAAV Production | UNIVERSITY OF KANSAS MEDICAL CENTER | QIU, JIANMING | 2022–2023 | name in abstract: Zolgensma |
| R41TR004338 | Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction | NABGEN, INC. | ASKEW, CHARLES H | 2023–2023 | name in abstract: Zolgensma |
| R01FD007226 | Flexible Platform for End-to-end Manufacturing of Gene Therapies to Advance Development of Treatments for Ultra-rare Diseases | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | HAN, JONGYOON | 2020–2022 | name in abstract: Zolgensma |
| R15NS120154 | The neuropathology of cerebellum in spinal muscular atrophy | DELAWARE STATE UNIVERSITY | SUN, JIANLI | 2022–2022 | name in abstract: Zolgensma |
| R21AI166293 | Identification of the AAVR-independent AAV entry pathway | UNIVERSITY OF KANSAS MEDICAL CENTER | QIU, JIANMING | 2021–2022 | name in abstract: Zolgensma |
| R41DK133021 | Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion | BEDROCK THERAPEUTICS, INC. | LI, CHENGWEN | 2022–2022 | name in abstract: Zolgensma |
| R21NS118165 | Facilitate by-stander effects by EV-mRNA cargo in AAV gene therapy for MPS IIIC | UNIV OF NORTH CAROLINA CHAPEL HILL | FU, HAIYAN | 2020–2020 | name in abstract: Zolgensma |
| R41AI155038 | Novel strategy to block AAV neutralizing anitbody activity | NABGEN, INC. | LI, CHENGWEN | 2020–2020 | name in abstract: Zolgensma |
| R41HL152923 | Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion | BEDROCK THERAPEUTICS, INC. | LI, CHENGWEN | 2020–2020 | name in abstract: Zolgensma |
Notes
AAV9 gene replacement for 5q spinal muscular atrophy. One program covering both formulations: the intravenous one (Zolgensma, onasemnogene abeparvovec-xioi, FDA 2019) and the intrathecal one (Itvisma, onasemnogene abeparvovec-brve, FDA 2025-11, for patients 2 years and older). SPEC section 1 says a new route or formulation of the same construct is not a new program, so they share this ID and have an approval row each; the FDA's four-letter suffixes differ but the INN does not. The EU authorisation was conditional in 2020 and became full on 2022-05-17.
How to cite
onasemnogene abeparvovec (AXP000250.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000250.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.